Known safety concerns, contraindications, and risk factors.
BPC-157, Larazotide acetate, KPV, and LL-37 are investigational compounds without approved human indications in most major jurisdictions. BPC-157 is a Category 2 bulk drug substance in the US (barred from compounding pharmacies) and WADA-prohibited for competitive athletes. Larazotide's Phase III trial was discontinued in 2022 with no marketed product. KPV and LL-37 are research compounds with small pilot human datasets. This protocol is not medical advice, not a prescription, and not a recommendation to self-administer any substance. Human evidence for this class is sparse — the majority of the dossier is preclinical. Every decision to use a peptide in this class is being made on mechanistic inference, not large-scale human trial outcomes. If you choose to proceed, do so with qualified medical supervision, verified pharmaceutical-grade or certificate-of-analysis-backed sourcing, and full awareness of the legal and athletic-regulatory status in your country.
Active autoimmune disease (LL-37 specifically)
LL-37 is immunostimulatory. In lupus, Hashimoto's, rheumatoid arthritis, psoriasis, and other active autoimmune conditions, administration has been reported to aggravate symptoms via immune activation.
Active or recent malignancy (BPC-157 specifically)
BPC-157 upregulates VEGF and drives angiogenesis. In active or recent cancer, the theoretical risk of accelerating tumour growth has not been excluded by clinical data.
Pregnancy or breastfeeding (entire class)
Clinical trials routinely excluded pregnant and breastfeeding participants. Human safety data is absent across all four peptides in this class, not reassuring.
Competitive athletes under WADA jurisdiction (BPC-157)
BPC-157 is on the WADA Prohibited List under S0/S2 categories. Detection constitutes an anti-doping violation with career-threatening consequences.
Concurrent NSAID therapy (BPC-157)
NSAIDs inhibit prostaglandin synthesis and counteract BPC-157's repair effect in animal models. Not a safety risk, but a therapeutic contradiction — the peptide is working against an active pharmacological brake.
Inflammatory bowel disease on surveillance endoscopy
Larazotide is mechanistically relevant to IBD and has been investigated in that context. The theoretical dysplasia risk from sustained proliferative repair in chronic mucosal injury warrants continued surveillance rather than relaxation.
Any user without verified pharmaceutical-grade or CoA-backed product
Grey-market contamination is the dominant documented source of harm in this class. Without a lot-matched certificate of analysis confirming sequence identity, purity, and endotoxin level, the safety of any administration is unquantifiable.